Although the median time to first SBM in patients treated with lubiprostone was reduced by almost half compared with that of placebo (28.5 vs 46.0 hours, respectively), the difference between treatment groups did not reach statistical significance ( P = 0.053).
← all excerpts
A randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain.
3
0.0530
0.0530
The sentences
The overall change from baseline in SBM frequency was also significantly greater with lubiprostone compared with placebo (mean, 2.2 vs 1.6 SBMs/week, P = 0.004); at week 12, the same pattern was observed but did not achieve significance (Figure 1 A).
The use of any kind of rescue medication was similar in the lubiprostone and placebo arms at month 1 (100/207 [48.3%] vs 100/206 [48.5%], respectively; P = 0.962); there was a nonsignificant trend for a reduced use of rescue medications in patients treated with lubiprostrone as compared with patients receiving placebo at months 2 (63/175 [36.0%] vs 78/184 [42.4%]; P = 0.216) and 3 (49/155 [31.6%] vs 67/160 [41.9%]; P = 0.059).